Summary

The world will fail to save the lives of 1 million women by 2030 if we do not join forces to accelerate progress towards Sustainable Development Goal (SDG) 3.1 to reduce maternal mortality. PPH remains the leading cause of maternal mortality, accounting for over 20% of all maternal deaths reported globally. Death from PPH is largely preventable and has been nearly eliminated in high-income countries (HICs). Today, nearly all maternal deaths from PPH occur in sub-Saharan Africa and south Asia.


Ferring’s Project Family Safe Birth Commitment is a global partnership with the vision that every woman, no matter where she lives, should have access to a safe birth, including quality care and necessary treatment during pregnancy and childbirth.

Our commitment is to help protect the lives of 20 million women and their families by 2030 by reducing preventable maternal deaths from postpartum haemorrhage (PPH).


We will achieve this commitment by providing equitable access to Ferring’s innovation, a heat-stable formulation of carbetocin (HSC) for the prevention of PPH after all births, which was developed through a public-private partnership to address disparities in maternal health care in low- and lower middle-income countries (L&LMICs).


Towards 2030, we will work with partners, governments and stakeholders, making this essential medicine available long term at a not-for-profit, affordable price to public and not-for-profit health facilities in L&LMICs.

In alignment with normative guidelines set out by the World Health Organization (WHO) and treatment protocols provided by governments and professional societies, as well as priorities set out in the WHO Post-Partum Haemorrhage Roadmap to Combat Post-Partum Haemorrhage between 2023 and 2030, we are committed to:


• Enabling long term access to HSC in L&LMICs, and countries with MMR > 140/100,000 live births;

• Supporting HSC registrations, supply and introductions to meet public health demands;

• Providing and supporting training on the appropriate use of HSC;

• Supporting research on PPH;

• Working in collaboration with governments, professional societies, health care providers, partners and other stakeholders to achieve all this.


Project lead:

Charlotte Ersboell, Senior Advisor, Ferring Pharmaceuticals